Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Invega Prior Auth Update | OpenPaye…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Invega Sustenna and Invega Trinza Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for the long-acting injectable paliperidone formulations Invega Sustenna and Invega Trinza in adults with schizophrenia or schizoaffective disorder.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyInvega Sustenna and Invega Trinza Prior Authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJan 31, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Invega Trinza only after adequate treatment with Invega Sustenna for at least 4 months.
    SourceLink
    POLICY UPDATE CHANGES

    The policy updated its preauthorization criteria on February 18, 2025.

    The policy added a Beers Criteria note addressing antipsychotic risks in older adults and patients with dementia or delirium.

    The policy added an adverse-reactions section listing central nervous system depression, tachycardia, dystonias, and Parkinsonism.

    2Covered formulations addressed
    MonthlyInvega Sustenna dosing interval
    Every 3 monthsInvega Trinza dosing interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4 months
    Required Sustenna treatment before Trinza
    2Adult Sustenna indication categories

    Covered Indications and Formulations

    Invega Sustenna

    Covered when ALL of the following are met:

    Invega Sustenna eligibility

    • Adult patient: Patient is an adult.
    • ONE of the following covered indications

      • Schizophrenia: Patient has schizophrenia.
      • Schizoaffective disorder: Patient has schizoaffective disorder treated as monotherapy or as an adjunct to a mood stabilizer or antidepressant.

    Invega Trinza

    Covered when ALL of the following are met:

    Invega Trinza eligibility

    • Qualifying diagnosis: Patient has schizophrenia.
    • Required prior treatment: Patient has been adequately treated with Invega Sustenna for at least 4 months.At least 4 months of adequate Invega Sustenna treatment

    Prior Authorization Requirements

    Prior Authorization

    Prior Authorization Required for Invega Sustenna

    Submit a prior authorization for Invega Sustenna when requested for an adult with schizophrenia or schizoaffective disorder. For schizoaffective disorder, treatment may be monotherapy or an adjunct to a mood stabilizer or antidepressant.

    • Adult schizophrenia
    • Adult schizoaffective disorder: monotherapy or adjunctive treatment with a mood stabilizer or antidepressant
    Step Therapy

    Invega Trinza Requires Prior Sustenna Treatment

    Submit a prior authorization for Invega Trinza only when it is being used to treat schizophrenia after the patient has been adequately treated with Invega Sustenna.

    • Indication: schizophrenia
    • Prerequisite: adequate prior treatment with Invega Sustenna

    Medication Background

    Paliperidone is an atypical antipsychotic and the primary active metabolite of risperidone. Its therapeutic effects are associated with mixed central serotonergic and dopaminergic antagonism. Invega Sustenna is a long-acting injectable formulation administered monthly, while Invega Trinza is administered every three months. This policy addresses the Sustenna and Trinza formulations for schizophrenia and schizoaffective disorder.

    Formulation Definitions

    Paliperidone
    Drug classAtypical antipsychotic
    Relationship to risperidonePrimary active metabolite of risperidone
    Therapeutic mechanismMixed central serotonergic and dopaminergic antagonism
    Invega Sustenna
    FormulationLong-acting injectable paliperidone
    AdministrationInjection
    Dosing intervalMonthly

    Initial Authorization Criteria

    Invega Sustenna Initial Authorization

    Initial authorization is available when ONE of the following indications is documented in an adult:

    ONE of the following indications

    • Schizophrenia: Adult patient with schizophrenia.
    • Schizoaffective disorder: Adult patient with schizoaffective disorder treated as monotherapy or as an adjunct to a mood stabilizer or antidepressant.

    Invega Trinza Initial Authorization

    Initial authorization is available when ALL of the following are met:

    Trinza initial authorization

    Required Treatment Sequence

    StepMedicationRequirementDuration
    1Invega SustennaAdequate treatment before starting Invega TrinzaAt least 4 months

    Dosing and Quantity Limits

    Quantity Limit
    DrugInvega Sustenna
    Quantity limitOne injection
    Dosing intervalMonthly
    Quantity Limit
    DrugInvega Trinza
    Quantity limitOne injection
    Dosing intervalEvery three months
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyInvega Sustenna and Invega Trinza Prior Authorization
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJan 31, 2023
    Last ReviewFeb 20, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Invega Trinza only after adequate treatment with Invega Sustenna for at least 4 months.
    SourceLink
    On This Page
    Covered Indications and FormulationsPrior Authorization RequirementsMedication BackgroundFormulation DefinitionsInitial Authorization CriteriaRequired Treatment SequenceDosing and Quantity Limits
    Step Therapy

    Required Four-Month Sustenna Trial

    Document that the patient received adequate Invega Sustenna treatment for at least 4 months before initiating Invega Trinza.

    • Minimum prerequisite duration: at least 4 months of adequate Invega Sustenna treatment
    Invega Trinza
    FormulationLong-acting injectable paliperidone
    AdministrationInjection
    Dosing intervalEvery three months
    Diagnosis: Patient has schizophrenia.
  1. Prior Invega Sustenna treatment: Patient has been adequately treated with Invega Sustenna before starting Invega Trinza.At least 4 months of adequate Invega Sustenna treatment